Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
BioSeek and Merck Serono Extend 2008 Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
BioSeek, Inc. has announced that it has signed a new, three-year collaboration agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, extending and expanding the companies’ previous 2008 compound profiling agreement.
Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.
“The benchmarking studies carried out by BioSeek for Merck Serono during 2008 demonstrated that, with proper study design and interactive follow-up, BioMAP systems can be used to reliably identify and advance promising molecules through preclinical evaluation. Our scientists have worked closely and productively with the Merck Serono team, and we look forward to our continuing research with them,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in vascular inflammation, cardiovascular and respiratory diseases, fibrosis and related clinical indications.
Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in the BioMAP Database. Assessment with BioMAP provides early insight into human pharmacological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.
“The benchmarking studies carried out by BioSeek for Merck Serono during 2008 demonstrated that, with proper study design and interactive follow-up, BioMAP systems can be used to reliably identify and advance promising molecules through preclinical evaluation. Our scientists have worked closely and productively with the Merck Serono team, and we look forward to our continuing research with them,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in vascular inflammation, cardiovascular and respiratory diseases, fibrosis and related clinical indications.
Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in the BioMAP Database. Assessment with BioMAP provides early insight into human pharmacological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
